→ After a protracted court battle in the United States to thwart generic competition of its blockbuster opioid addiction treatment Suboxone ultimately proved in vain, UK’s Indivior decided to get ahead of the curve on Tuesday, announcing that it was launching its own cut-price version of the drug. On Friday, Mylan $MYL launched its copycat. It remains to be seen which generic will be cheaper.
→ After years of positioning itself as a tiny biotech player up against giant rivals in the CGRP migraine field, Alder BioPharmaceuticals $ALDR has finally submitted a BLA for eptinezumab, bringing it one step closer to securing a last-place finish. Despite daunting competition from Novartis $NVS/Amgen $AMGN, Teva $TEVA and Eli Lilly $LLY, Alder believes its quarterly IV therapy — if approved — will stand out in the commercial fight upon launch Q1 2020. Or a buyer can swing by and pick up what would be a relatively cheap one-drug company, as recently suggested by Leerink’s Geoffrey Porges.
→ UK-based rare disease drug developer Mereo — which is listed on the London stock exchange — officially withdrew its IPO application to list on the Nasdaq on Thursday, after announcing in late December that it would use the flailing California biotech OncoMed $OMED to reverse-merge itself onto the exchange.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription